The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Genentech; InnoPharmax; Lilly; Merck Serono; Novartis; Pfizer; Roche; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Dong-Wan Kim
Consultant or Advisory Role - Novartis
Wu-Chou Su
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Johan F. Vansteenkiste
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche
Research Funding - AstraZeneca; Lilly; Roche
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Bin Peng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ying Gong
Employment or Leadership Position - Novartis
Sylvia Zhao
No relevant relationships to disclose
Taro Amagasaki
Employment or Leadership Position - Novartis
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Daniel Shao-Weng Tan
Honoraria - Bayer; Novartis
Research Funding - Novartis